This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Flom-Halvorsen, H. I Articles by Øystese, R Search for Related Content PubMed PubMed Citation Articles by Flom-Halvorsen, H. I Articles by Øystese, R Social Bookmarking                         What's this?

Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction

Oslo Heart Center, Oslo, Norway, Research Institute for Internal Medicine, University of Oslo, Rikshospitalet, Oslo, Norway, hannef{at}klinmed.uio.no

E Øvrum

Oslo Heart Center, Oslo, Norway

F Brosstad

Research Institute for Internal Medicine, University of Oslo, Rikshospitalet, Oslo, Norway

G Tangen

Oslo Heart Center, Oslo, Norway

M AL Ringdal

Oslo Heart Center, Oslo, Norway

R Øystese

Oslo Heart Center, Oslo, Norway

Objective: The two most commonly used heparin-coated systems for cardiopulmonary bypass (CPB) are the Carmeda Bio-Active Surface (CBAS) (Medtronic, Minneapolis, MN, USA) and the Duraflo II coating (Baxter Healthcare, Irvine, CA, USA). The two surfaces are technically unequal and previous experimental studies have demonstrated disparities in effects on the immune system and blood cells. However, little is known concerning the influence of the two surfaces on markers for brain and myocardial dysfunction.

Methods: Forty patients undergoing elective, primary coronary bypass grafting with CPB were prospectively randomized to either the CBAS system or the Duraflo II circuit. During and after CPB, biological markers for brain dysfunction and myocardial injury were analysed.

Results: Both markers for brain dysfunction S-100B and neuron-specific enolase (NSE) increased significantly during CPB (p =0.01). The elevation during bypass correlated significantly with the duration of CPB (r = 0.39 and r= 0.38, respectively, both p< 0.02). NSE was somewhat more elevated in the Duraflo II group at the end of CPB (p =0.01) and 5 h after CPB (p= 0.02); for S-100B, there were no intergroup differences. Also, the markers related to myocardial injury, myoglobin and creatine kinase (CK-MB) mass increased during CPB (p= 0.01), while elevation of troponin-I occurred 5 h after CPB (p= 0.01). There were no statistically significant intergroup differences. No significant correlation was seen between the release of cardiac markers and the duration of CPB. The clinical course was similar in both groups.

Conclusions: Except for a slightly higher elevation of NSE at the end of CPB and 5 h after CPB in the Duraflo II group, there were no significant differences between the CBAS group and the Duraflo II group concerning markers for brain and myocardial dysfunction.

Perfusion, Vol. 17, No. 5, 339-345 (2002)
DOI: 10.1191/0267659102pf594oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				O. Mangoush, S. Purkayastha, S. Haj-Yahia, J. Kinross, M. Hayward, F. Bartolozzi, A. Darzi, and T. Athanasiou Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1058 - 1069. [Abstract] [Full Text] [PDF]

				The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF]

				R. Taneja and D. C. Cheng Con: Heparin-Bonded Cardiopulmonary Bypass Circuits Should Be Routine for All Cardiac Surgical Procedures Anesth. Analg., December 1, 2006; 103(6): 1370 - 1372. [Full Text] [PDF]

				T Gourlay and P Connolly Does cardiopulmonary bypass still represent a good investment? The biomaterials perspective Perfusion, July 1, 2003; 18(4): 225 - 231. [Abstract] [PDF]